Axsome Therapeutics (AXSM) Tops Q2 EPS by 9c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.97), $0.09 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $150.04 million versus the consensus estimate of $139.31 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Chemours reaches $450M settlement over PFAS pollution at four sites
• Palantir (PLTR) call put ratio 1.8 calls to 1 put with a focus on June 127, 129 and 132 calls
• Europe's Largest Quay Cranes Arrive at DP World Southampton